Alumis-IRF5-Additional Targets

Alumis-IRF5-Additional Targets refers to an early-stage drug discovery program managed by Alumis (formerly Esker Therapeutics) that focuses on the inhibition of Interferon Regulatory Factor 5 (IRF5) and other undisclosed targets. IRF5 is a transcription factor that plays a critical role in the innate immune response by regulating the expression of pro-inflammatory cytokines, such as Type I interferons, TNF-alpha, and IL-12. Dysregulation of the IRF5 pathway is a known driver in the pathogenesis of various autoimmune and inflammatory conditions, most notably systemic lupus erythematosus (SLE). By targeting IRF5, Alumis aims to develop precision therapies that can modulate these inflammatory pathways. As of early 2024, the program remains in the discovery or preclinical phase, with specific lead molecules and modalities not yet publicly detailed.

Other names

Alumis IRF5 program